Intrexon Corporation (NYSE:XON)‘s stock had its “buy” rating reaffirmed by equities research analysts at Northland Securities in a note issued to investors on Friday. They presently have a $27.00 price objective on the biotechnology company’s stock. Northland Securities’ price objective would indicate a potential upside of 32.42% from the company’s previous close.

Several other research firms also recently commented on XON. Griffin Securities reaffirmed a “buy” rating and issued a $55.00 price target on shares of Intrexon Corporation in a research note on Friday. BidaskClub downgraded shares of Intrexon Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 22nd. JMP Securities reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Intrexon Corporation in a research note on Thursday. Finally, Zacks Investment Research downgraded shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $43.20.

Shares of Intrexon Corporation (XON) traded down 5.69% during trading on Friday, hitting $19.23. 586,627 shares of the company traded hands. The company’s market capitalization is $2.32 billion. Intrexon Corporation has a 52 week low of $17.03 and a 52 week high of $32.90. The company has a 50 day moving average price of $19.03 and a 200 day moving average price of $21.10.

Intrexon Corporation (NYSE:XON) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The company had revenue of $54.40 million for the quarter, compared to the consensus estimate of $57.17 million. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The firm’s revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.42) EPS. On average, analysts expect that Intrexon Corporation will post ($0.87) earnings per share for the current year.

WARNING: “Intrexon Corporation (XON) Given Buy Rating at Northland Securities” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/06/intrexon-corporation-xon-given-buy-rating-at-northland-securities.html.

In other Intrexon Corporation news, Director Robert B. Shapiro bought 2,850 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were acquired at an average price of $17.50 per share, with a total value of $49,875.00. Following the transaction, the director now owns 43,157 shares of the company’s stock, valued at approximately $755,247.50. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Dean J. Mitchell bought 5,000 shares of the business’s stock in a transaction on Friday, August 11th. The shares were acquired at an average cost of $18.33 per share, for a total transaction of $91,650.00. Following the transaction, the director now directly owns 18,103 shares in the company, valued at approximately $331,827.99. The disclosure for this purchase can be found here. Insiders purchased a total of 144,569 shares of company stock worth $2,719,429 in the last ninety days. 55.10% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of XON. State Street Corp increased its position in Intrexon Corporation by 34.0% during the 1st quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock valued at $53,664,000 after purchasing an additional 687,406 shares during the period. First Trust Advisors LP increased its position in Intrexon Corporation by 32.5% during the 2nd quarter. First Trust Advisors LP now owns 1,537,088 shares of the biotechnology company’s stock valued at $37,028,000 after purchasing an additional 376,780 shares during the period. Vanguard Group Inc. increased its position in Intrexon Corporation by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock valued at $84,954,000 after purchasing an additional 226,090 shares during the period. Credit Suisse AG increased its position in Intrexon Corporation by 273.7% during the 1st quarter. Credit Suisse AG now owns 183,555 shares of the biotechnology company’s stock valued at $3,638,000 after purchasing an additional 134,434 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Intrexon Corporation by 60.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 144,428 shares of the biotechnology company’s stock valued at $2,862,000 after purchasing an additional 54,179 shares during the period. 82.11% of the stock is currently owned by institutional investors and hedge funds.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon Corporation (NYSE:XON)

Receive News & Stock Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related stocks with our FREE daily email newsletter.